These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 7064531)

  • 1. [Various aspects of the interaction between the dopamine and opiate systems in schizophrenia].
    Anokhina IP
    Vestn Akad Med Nauk SSSR; 1982; (1):37-40. PubMed ID: 7064531
    [No Abstract]   [Full Text] [Related]  

  • 2. Dopamine agonists in the treatment of schizophrenia.
    Del Zompo M; Bocchetta A; Piccardi MP; Corsini GU
    Prog Brain Res; 1986; 65():41-8. PubMed ID: 3786793
    [No Abstract]   [Full Text] [Related]  

  • 3. Apomorphine and schizophrenia.
    Johns CA; Levy MI; Davis BM; Mohs RC; Kendler KS; Mathe AA; Trigos G; Horvath TB; Davis KL
    Psychopharmacol Bull; 1984; 20(1):103-7. PubMed ID: 6718635
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of apomorphine on schizophrenic symptoms.
    Smith RC; Tamminga C; Davis JM
    J Neural Transm; 1977; 40(2):171-6. PubMed ID: 323423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical effects of apomorphine in schizophrenia.
    Ferrier IN; Johnstone EC; Crow TJ
    Br J Psychiatry; 1984 Apr; 144():341-8. PubMed ID: 6372924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apomorphine reduces schizophrenic symptoms.
    Schaffer MH; Tamminga CA; Smith RC; Davis JM
    Psychopharmacol Bull; 1980 Jan; 16(1):55-7. PubMed ID: 6987694
    [No Abstract]   [Full Text] [Related]  

  • 7. Naloxone in the treatment of schizophrenia.
    Wen HL; Lo CW; Ho WK; Mehal ZD; Ng YH; Lam S; Ma L
    Mod Med Asia; 1978 Dec; 14(12):51-5. PubMed ID: 750907
    [No Abstract]   [Full Text] [Related]  

  • 8. Cholinergic aspects of schizophrenia.
    Tandon R
    Br J Psychiatry Suppl; 1999; (37):7-11. PubMed ID: 10211133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential influence of D1 and D2 dopamine receptors on acute opiate withdrawal in guinea-pig isolated ileum.
    Capasso A; Sorrentino L
    Br J Pharmacol; 1997 Mar; 120(6):1001-6. PubMed ID: 9134209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opiate antagonists for the treatment of schizophrenia.
    Welch EB; Thompson DF
    J Clin Pharm Ther; 1994 Oct; 19(5):279-83. PubMed ID: 7806598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of schizophrenia drugs: a focus on dopaminergic systems.
    Nikam SS; Awasthi AK
    Curr Opin Investig Drugs; 2008 Jan; 9(1):37-46. PubMed ID: 18183530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy of migraine by modulating dopamine hypersensitivity: its effect on mood and pain.
    Lai M; Loi V; Pisano MR; Del Zompo M
    Int J Clin Pharmacol Res; 1997; 17(2-3):101-3. PubMed ID: 9403364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Activity of dopaminergic endings of rat forebrain nuclei during electroconvulsive amnesia and reproduction of a "passive" avoidance conditioned reaction restored with apomorphine].
    Spiridonov VK; Nikiforov AF
    Zh Vyssh Nerv Deiat Im I P Pavlova; 1981; 31(2):409-11. PubMed ID: 7196660
    [No Abstract]   [Full Text] [Related]  

  • 14. Therapeutic possibilities of cysteamine in the treatment of schizophrenia.
    Pae CU; Lee C; Paik IH
    Med Hypotheses; 2007; 69(1):199-202. PubMed ID: 17166669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopaminergic modulation of impaired cognitive activation in the anterior cingulate cortex in schizophrenia.
    Dolan RJ; Fletcher P; Frith CD; Friston KJ; Frackowiak RS; Grasby PM
    Nature; 1995 Nov; 378(6553):180-2. PubMed ID: 7477319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Apomorphine in dyskinesia and psychomotor agitation].
    Stoliarov GV; Markova OF
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1982; 82(8):97-102. PubMed ID: 7136384
    [No Abstract]   [Full Text] [Related]  

  • 17. Serotonin and dopamine interactions in rodents and primates: implications for psychosis and antipsychotic drug development.
    Marek GJ
    Int Rev Neurobiol; 2007; 78():165-92. PubMed ID: 17349861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of D2 dopamine receptors in the nucleus accumbens in the opiate withdrawal syndrome.
    Harris GC; Aston-Jones G
    Nature; 1994 Sep; 371(6493):155-7. PubMed ID: 7915401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Towards a muscarinic hypothesis of schizophrenia.
    Raedler TJ; Bymaster FP; Tandon R; Copolov D; Dean B
    Mol Psychiatry; 2007 Mar; 12(3):232-46. PubMed ID: 17146471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brain-derived neurotrophic factor in schizophrenia and its relation with dopamine.
    Guillin O; Demily C; Thibaut F
    Int Rev Neurobiol; 2007; 78():377-95. PubMed ID: 17349867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.